CT/NG Testing Market by Product (Assays & Kits, Instruments & Analyzers), Testing Type (Lab Tests, PoC Tests), Technology, End User - Global Forecast 2024-2030

CT/NG Testing Market by Product (Assays & Kits, Instruments & Analyzers), Testing Type (Lab Tests, PoC Tests), Technology, End User - Global Forecast 2024-2030

The CT/NG Testing Market size was estimated at USD 1.63 billion in 2023 and expected to reach USD 1.74 billion in 2024, at a CAGR 7.41% to reach USD 2.69 billion by 2030.

The CT/NG testing is primarily focused on the accurate diagnosis, management, and prevention of sexually transmitted infections (STIs), including Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). The increasing prevalence of chlamydia and gonorrhea infections worldwide and rising awareness about the risks associated with untreated STIs also fuel the need for timely identification and appropriate treatment options. Technological diagnostics advancements offer opportunities for improving accuracy in detecting CT/NG infections while minimizing turnaround times. The development of POC test kits, allowing rapid results without any need for laboratory infrastructure, has gained immense popularity since it enables faster clinical decision-making. However, high costs associated with advanced diagnostic tests coupled with variations in government regulations across different countries concerning diagnostic tests limit product penetration worldwide. Nevertheless, the growing adoption of molecular diagnostics methods and government-led initiatives to promote STI screening programs to facilitate early detection and prevention of complications associated with untreated infections contribute positively to the growth of the CT/NG testing market.

Regional Insights

A growing demand for point-of-care diagnostics for sexually transmitted infections (STIs), increasing prevalence of chlamydia and gonorrhea infections, and government initiatives targeting early detection and treatment have expanded the need for CT/NG testing. In the EU countries, a rising focus on STI prevention programs to address the public health challenges investments for improving diagnostic methods through research contribute to the CT/NG testing market. The Middle East & Africa region exhibits significant potential for CT/NG testing growth due to increased government efforts towards improving STI awareness and access to healthcare services. With a large population and growing awareness around sexual health following education campaigns by the Asia-Pacific government, the region presents a lucrative CT/NG testing market.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the CT/NG Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Increasing prevalence of STIs worldwide
• Growing awareness about the consequences of untreated infections
• Rising need for point-of-care (POC) testing devices

Market Restraints

• High costs associated with advanced diagnostic equipment

Market Opportunities

• Government initiatives for promoting sexual health education
• Integration of automation systems to enhance workflow efficiency

Market Challenges

• Emergence of antibiotic-resistant strains by CT/NG testing

Market Segmentation Analysis

• Product: Rapid adoption of instruments and analyzers for providing consistent results
• Testing Type: Gaining popularity of PoC tests for CT/NG
• Technology: Advancing Polymerase Chain Reaction (PCR)-based CT/NG testing for prioritizing accuracy over cost and speed
• End User: Popularity of point-of-care testing for hospital and clinic settings

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the CT/NG Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the CT/NG Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

binx health Announces Strategic Supply Agreement with Afaxys to Expand Sexual Health Test Access to Thousands of Clinics Nationally

Healthcare technology and diagnostics company,binx health, collaborated with Afaxys Group Services LLC to expand access to sexual health and wellness testing nationwide through their group purchasing organization (GPO). Under this agreement, thousands of clinics across the United States have access to binx's FDA-cleared, CLIA-waived point-of-care test for chlamydia (CT) and gonorrhea (NG), as well as their at-home digital health platform.

Bio-Rad Launches Exact Diagnostics CT/NG, STI Run Controls

Bio-Rad Laboratories has introduced two molecular controls for CT/NG testing in its Exact Diagnostics range. These controls play an important role in ensuring accurate and reliable assay results. The first control, the CT/NG Positive Run Control, is designed to confirm the presence of Chlamydia trachomatis and Neisseria gonorrhoeae in the assay. On the other hand, the STI Negative Run Control is essential for monitoring the absence of C. trachomatis and N. gonorrhoeae in the samples.

Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise

Abbott recently obtained FDA clearance for its Alinity m STI Assay, a groundbreaking test that can concurrently identify and differentiate four prevalent sexually transmitted infections (STIs). The Alinity m STI test allows healthcare providers to save time, enhance efficiency, and provide better patient care.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the CT/NG Testing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the CT/NG Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Binx Health, Inc., Bio-Rad Laboratories, Inc., Bioneer Corporation, Danaher Corporation, ELITech Group SAS, F. Hoffmann-La Roche Ltd., Geneproof A.S., Genetic Signatures Ltd., Goffin Molecular Technologies B.V., Hologic, Inc., Meridian Bioscience Inc., Microbiologics, Inc., Molbio Diagnostics Pvt. Ltd., Operon S.A., PerkinElmer Inc., QIAGEN N.V., Sansure Biotech Inc., Seegene, Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Tianlong Technology Co., Ltd., Vircell S.L., and Visby Medical, Inc..

Market Segmentation & Coverage

This research report categorizes the CT/NG Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
• Assays & Kits
• Instruments & Analyzers
• Testing Type
• Lab Tests
• PoC Tests
• Technology
• Immunodiagnostics
• Isothermal Nucleic Acid Amplification Technology
• Polymerase Chain Reaction
• End User
• Clinical Laboratories
• Hospitals & Clinics

Region

• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year